- Home
- UAMY vs RAPT Comparison
UAMY vs RAPT Comparison
Compare UAMY & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UAMY
- RAPT
- Stock Information
- Founded
- UAMY 1968
- RAPT 2015
- Country
- UAMY United States
- RAPT United States
- Employees
- UAMY N/A
- RAPT N/A
- Industry
- UAMY Metal Fabrications
- RAPT Biotechnology: Pharmaceutical Preparations
- Sector
- UAMY Industrials
- RAPT Health Care
- Exchange
- UAMY Nasdaq
- RAPT Nasdaq
- Market Cap
- UAMY 67.5M
- RAPT 65.6M
- IPO Year
- UAMY N/A
- RAPT 2019
- Fundamental
- Price
- UAMY $0.69
- RAPT $1.69
- Analyst Decision
- UAMY
- RAPT Hold
- Analyst Count
- UAMY 0
- RAPT 9
- Target Price
- UAMY N/A
- RAPT $7.25
- AVG Volume (30 Days)
- UAMY 853.0K
- RAPT 258.0K
- Earning Date
- UAMY 11-11-2024
- RAPT 11-11-2024
- Dividend Yield
- UAMY N/A
- RAPT N/A
- EPS Growth
- UAMY N/A
- RAPT N/A
- EPS
- UAMY N/A
- RAPT N/A
- Revenue
- UAMY $9,862,364.00
- RAPT N/A
- Revenue This Year
- UAMY N/A
- RAPT N/A
- Revenue Next Year
- UAMY N/A
- RAPT N/A
- P/E Ratio
- UAMY N/A
- RAPT N/A
- Revenue Growth
- UAMY 18.08
- RAPT N/A
- 52 Week Low
- UAMY $0.17
- RAPT $1.66
- 52 Week High
- UAMY $0.82
- RAPT $27.35
- Technical
- Relative Strength Index (RSI)
- UAMY 48.42
- RAPT 41.09
- Support Level
- UAMY $0.67
- RAPT $1.66
- Resistance Level
- UAMY $0.74
- RAPT $1.93
- Average True Range (ATR)
- UAMY 0.06
- RAPT 0.20
- MACD
- UAMY -0.01
- RAPT -0.00
- Stochastic Oscillator
- UAMY 16.52
- RAPT 4.29
About UAMY United States Antimony Corporation
United States Antimony Corp is a fully integrated mining, transportation, milling, smelting, and selling company. It has four operating segments: United States Antimony, Mexican antimony, zeolite, and Precious metals. Its products and services include antimony; silver; gold; zeolite products; and storage, handling, & packaging services. The company's geographical segments are the United States, Canada, and Mexico, of which the vast majority of its revenue comes from the United States.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.